What is HC Wainwright’s Forecast for DNLI FY2027 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at HC Wainwright reduced their FY2027 EPS estimates for Denali Therapeutics in a research report issued on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1.68 for the year, down from their previous forecast of $1.69. HC Wainwright currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.53) per share.

Other equities research analysts also recently issued reports about the stock. Citigroup upped their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. JPMorgan Chase & Co. decreased their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Jefferies Financial Group raised their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $38.90.

Denali Therapeutics Stock Up 5.9 %

Shares of DNLI stock opened at $31.35 on Friday. The stock has a 50-day simple moving average of $27.81 and a 200 day simple moving average of $23.51. The stock has a market capitalization of $4.49 billion, a P/E ratio of -11.00 and a beta of 1.40. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $32.13.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the company earned ($0.72) earnings per share.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Ryan J. Watts sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now directly owns 235,807 shares in the company, valued at approximately $6,529,495.83. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DNLI. EP Wealth Advisors LLC purchased a new stake in shares of Denali Therapeutics during the first quarter worth $831,000. Edgestream Partners L.P. purchased a new stake in shares of Denali Therapeutics during the 1st quarter worth about $2,301,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Denali Therapeutics during the 1st quarter valued at about $4,330,000. Swiss National Bank grew its stake in shares of Denali Therapeutics by 0.7% in the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after buying an additional 1,500 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new position in Denali Therapeutics in the first quarter worth approximately $447,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.